ArticleTherapeutic advances in chronic disease2021
Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study.
Article in Therapeutic advances in chronic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The prevalence of obstructive sleep apnea-hypopnea syndrome in patients with multiple sclerosis: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.Frontiers in immunology · 2021Pooled it
- Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS.Neurology and therapy · 2025Article
- An Association of Framingham Risk Score with Patient Determined Disease Steps in a Cohort of Relapsing-Remitting Multiple Sclerosis Patients: An Italian Real-World Monocentric Experience.Current neuropharmacology · 2025Observational
- Polypharmacy in Multiple Sclerosis: Prevalence, Risks, and Mitigation Strategies.Current neurology and neuroscience reports · 2023Review
- Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis.Journal of clinical medicine · 2023Article
- Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review.Journal of clinical medicine · 2023Review
- Polypharmacy and multiple sclerosis: A population-based study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described 'spasticity-plus syndrome'.European journal of neurology · 2022Article
- InjectableNeural regeneration research · 2022Article
- Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis.BMC health services research · 2022Article
- Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications.Frontiers in neurology · 2022Article
- Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases.Frontiers in pharmacology · 2022Article
- Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review.International journal of environmental research and public health · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe aimed to examine the frequency of polypharmacy in a large cohort of patients at the time of diagnosis of relapsing-remitting multiple sclerosis (RRMS) and to explore its effects on discontinuation of first disease-modifying treatment (DMT) using survival analysis.
methodsThis was a cohort ambispective single-centre study. We enrolled RRMS patients starting their first DMT between 1st January 2013 and 31st December 2015. According to the number of medicines prescribed (except DMTs), we divided the patients into three groups: no-poly RRMS, minor-poly RRMS (from one to three medications), and major-poly RRMS (more than three medications).
resultsA total of 392 RRMS patients were enrolled (mean age 41.1). The minor-poly RRMS group included 61 patients (15.6%) and the major-poly RRMS group included 112 (28.6%). Individuals in these groups were older and had higher median body mass index (BMI) than patients in the no-poly RRMS group (
conclusionPolypharmacy was more common in older RRMS patients with high BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.